Item 3.02 | Unregistered Sales of Equity Securities. |
CytoDyn Inc. (the “Company”) is providing this disclosure because, as of February 24, 2023, its unregistered sales of equity securities that were not previously reported, in the aggregate, exceeded 5% of the shares of its common stock outstanding as of February 1, 2023.
Private Placement of Common Stock and Warrants through Placement Agent
In January and February 2023, the Company continued a private offering to accredited investors of units through a placement agent (the “Placement Agent Offering”). Each unit will consist of one share of common stock and one warrant to purchase one share of common stock. The final purchase price per unit will be equal to 90% of (i) the intraday volume weighted average price of the common stock as of the first closing, which occurred on January 12, 2023, and (ii) the intraday volume weighted average price of the common stock on the date of the final closing in the Placement Agent Offering, whichever is lower; provided that the purchase price will not be higher than $0.23 per unit. From February 1 to February 24, 2023, the Company had received binding subscription agreements to purchase units at a total purchase price of approximately $3.6 million, or an estimated total of approximately 15.7 million units, based on an assumed purchase price of $0.23 per unit.
The warrants to be issued in the Placement Agent Offering will have a five-year term and an exercise price of $0.50 per share. The warrants will be exercisable in full when issued. Except as described above, the terms of the warrants will be substantially similar to the form of warrant filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 7, 2021.
As previously disclosed on the Company’s Form 8-K filed on February 1, 2023, the Company has agreed to pay a cash fee equal to 12% of the gross proceeds received from qualified investors in the Placement Agent Offering, a one-time non-accountable expense fee of $25,000 in the aggregate for all closings in the Placement Agent Offering, and has also agreed to issue to the placement agent or its designees warrants with a 10-year term to purchase 15% of the total number of shares of common stock sold to qualified investors in the Placement Agent Offering.
The Company has agreed to use commercially reasonable efforts to prepare and file with the Securities and Exchange Commission (the “SEC”), and cause the SEC to declare effective, a registration statement under the Securities Act of 1933, as amended (the “Securities Act”) covering the resale of the shares and warrants to purchase shares of common stock sold in the Offering.
The Company is relying on the exemption provided by Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act in connection with the Placement Agent Offering.
Direct Investment by Dr. Cyrus Arman, President of the Company
On February 13, 2023, the Company accepted a $100,000 direct investment from Dr. Cyrus Arman, the President of the Company. This investment was made directly with the Company, with no placement agent serving as an intermediary. The terms of the investment will be identical to those of the Placement Agent Offering described above. Based on an assumed purchase price of $0.23 per unit, Dr. Arman would receive 434,782 units upon closing of his investment.
The Company is relying on the exemption provided by Section 4(a)(2) of the Securities Act in connection with the direct investment.
Warrant Issuance to Dr. David F. Welch, or One or More Affiliates
As previously reported in the Company’s Current Report on Form 8-K filed on February 17, 2022, the Company entered into a Surety Bond Backstop Agreement with David Fairbank Welch, both individually and in his capacity as trustee of a revocable trust, LRFA, LLC, a Delaware limited liability company, and certain other related parties (collectively, the “Indemnitors”), effective February 14, 2022. Under the agreement, the Indemnitors agreed to assist the Company in obtaining a surety bond (the “Surety Bond”) for posting in connection with the Company’s ongoing litigation with Amarex Clinical Research, LLC, by, among other things, agreeing to indemnify the issuer of the Surety Bond with respect to the Company’s obligations under the Surety Bond.